USPTO serial 79280774
ZELIRA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 1, 2022
- Examiner
- TRUSILO, KELLY JEAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ZELIRA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Elizabeth M. O'Donoghue
Elizabeth M. O'Donoghue Stradley Ronon Stevens & Young, LLP30 Valley Stream ParkwayMalvern, PA 19355UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Preparations for medical purposes derived from cannabis for the prevention, management and treatment of opioid addiction, cancer including breast cancer, brain cancer and pancreatic cancer, pain, chronic pain, terminal illnesses, epilepsy, arthritis, crohn's disease, insomnia, diabetes, eczema, psychiatric diseases and disorders including mood disorders, anxiety disorders, sleep disorders, cognitive disorders, Alzheimer's, depression, autism and post-traumatic stress disorder; none of the foregoing being preparations to treat deficiencies of Alpha-One proteinase inhibitors; none of the goods being for the treatment and detection of cervical cancer and related infections | ACTIVE | — |
| 042 | Conducting clinical trials for others; research relating to science; provision of pharmaceutical research services; project management and planning of clinical trials, namely, consulting services for others in the field of design, planning, and implementation project management of clinical trials; research relating to pharmaceuticals; research relating to medicinal use of marijuana and cannabis; scientific research relating to medicinal use of cannabis; scientific research and development of medicinal cannabis products; medical research; scientific research for medical purposes; scientific research; none of the foregoing in relation to the treatment of deficiencies of Alpha-One proteinase inhibitors; none of the services being for the treatment and detection of cervical cancer and related infections | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ZELIRA THERAPEUTICS LIMITED
- Other trademarks owned by ZELIRA THERAPEUTICS LIMITED
- Other trademarks owned by ZELIRA THERAPEUTICS LIMITED
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ZELIRA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 22, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 2, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 2, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 1, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 1, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 2, 2022 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Dec 19, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 14, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 14, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 24, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 24, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 24, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 21, 2021 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Nov 21, 2021 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 5, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 4, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Sep 4, 2021 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 18, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 18, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 29, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 29, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 29, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 19, 2021 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Mar 24, 2021 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Mar 23, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 22, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 22, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 22, 2021 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Jan 2, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 4, 2020 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Nov 7, 2020 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Nov 3, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 3, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 3, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 3, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 3, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 18, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 24, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 24, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 23, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 22, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 29, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 27, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 20, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 16, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 12, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |